Articles by Rita Peters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Rita Peters

Drugs At What Cost

Jan 2, 2014

Generics, market dynamics, and global demand are changing drug spending patterns.

Uncertainty in the Workplace

Industry mergers, acquisitions and downsizing contribute to uncertainty in job security.
Dec 2, 2013

Industry mergers, acquisitions and downsizing contribute to uncertainty in job security in the European bio/pharmaceutical market.

Industry Optimism Outweighs Personal Job Security

Restructuring mutes employment optimism.
Dec 2, 2013

Pharmaceutical Technology's 2013 Employment Survey reveals some optimism for the industry's future performance, but ongoing concerns about individual job prospects.

New Funding and Approval Pathways Prove Popular

The JOBS Act and FDASIA show early signs of accelerating drug development.
Nov 2, 2013

The JOBS Act and FDASIA show early signs of accelerating drug development.

Filling a Gap in Drug Safety

As the Supreme Court ruled on generic-drug liability, FDA outlined new rules for warning labels.
Aug 2, 2013

As the Supreme Court ruled on generic-drug liability, FDA outlined new rules for warning labels.

The Pains of Change

Pharma and biotech companies, with the rest of the health care industry, must face change.
Jul 2, 2013

Pharma and biotech companies, with the rest of the health care industry, must face change.

Trust in the Pill Bottle

The Ranbaxy settlement provides a cautionary tale for patients, FDA, and drug manufacturers.
Jun 2, 2013

Ranbaxy's $500 million settlement for producing adulterated drugs and fradulent data provides a cautionary tale for patients, FDA, and drug manufacturers.

Pathway to Publication

Wanted: Article contributions on drug and process development topics.
May 2, 2013

Wanted: Article contributions on drug and process development topics.

FDA Will Not Approve Generics to Original OxyContin

Apr 17, 2013

The FDA approved updated labeling for Purdue Pharma L.P.?s reformulated OxyContin tablets, but also determined that it will not approve generic versions of the original OxyContin.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here